Knight Therapeutics Inc
TSX:GUD
Knight Therapeutics Inc
Revenue
Knight Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Revenue
CA$371.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
51%
|
CAGR 10-Years
100%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Revenue
CA$276.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Revenue
CA$320.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Revenue
CA$920.4m
|
CAGR 3-Years
154%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Revenue
$117.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Revenue
$2.3B
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Knight Therapeutics Inc
Glance View
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.
See Also
What is Knight Therapeutics Inc's Revenue?
Revenue
371.3m
CAD
Based on the financial report for Dec 31, 2024, Knight Therapeutics Inc's Revenue amounts to 371.3m CAD.
What is Knight Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
100%
Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for Knight Therapeutics Inc have been 15% over the past three years , 51% over the past five years , and 100% over the past ten years .
You don't have any saved screeners yet